Effects of consumption of the test food on the immune function in healthy Japanese subjects
- Conditions
- Healthy Japanese subjects
- Registration Number
- JPRN-UMIN000046991
- Lead Sponsor
- ORTHOMEDICO Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who have autoimmune disease 5. Subjects who use or take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily 6. Subjects who cannot stop taking the food containing lactic acid bacteria (such as natto, yogurt, and fermented food) or lactic fermenting beverage during the test period 7. Subjects who currently taking medications (including herbal medicines) and supplements 8. Subjects who are taking immunosuppressants such as steroids 9. Subjects who are allergic to medicines and/or the test beverage related products 10. Subjects who have pollen allergy or perennial allergic rhinitis 11. Subjects who are pregnant, breast-feeding, and planning to become pregnant 12. Subjects who suffer from COVID-19 13. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 14. Subjects who are judged as ineligible to participate in the study by the physician 15. Subjects who have received vaccination for influenza within the last three months before the agreement to participate in this trial 16. Subjects who plan to receive vaccination for SARS-Cov-2 during the test period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method